Regen Biopharma Inc (RGBAD)

[trazbull]

Regen BioPharma, Inc. Research Demonstrates Ex-Vivo Immune Suppression With Novel NR2F6 Activators
Novel Activators Demonstrate Selective Inhibition of IL-17a and IL-2

NEWS PROVIDED BY
Regen BioPharma, Inc.
08:00 ET
SHARE THIS ARTICLE

SAN DIEGO, July 25, 2017 /PRNewswire/ --

Regen BioPharma Inc. (OTCQB: RGBP) and (OTCQB: RGBPP) today reported continued progress in Regen's development of small molecule drugs that activate and inhibit NR2F6. The Company reports that recently identified novel chemical compounds that activate NR2F6 also selectively inhibit cytokines secreted from activated immune cells. This indicates that researchers have identified a compound that appears to be effective in treating autoimmune diseases with virtually no toxicity. Research was conducted by ChemDiv, Inc. (an internationally recognized contract research organization) which has been retained by Regen to conduct research and experiments on Regen's behalf.

The NR2F6 nuclear receptor has been identified as a potentially very important immune cell inhibitor (an immune checkpoint) and cancer stem cell differentiator. The NR2F6 program at Regen aims to identify antagonists of NR2F6 in an effort to unleash the cancer-killing potential of a patient's own immune system as well as identifying agonists which should suppress the immune system in diseases where the immune system is over-activated, such as autoimmunity.

"We tested three recently-identified agonists which share a privileged structure for their ability to inhibit cytokine production in stimulated immune cells," says Harry Lander, Ph.D., MBA, President and Chief Scientific Officer of Regen. "After stimulating the immune cells in the presence or absence of our compounds, we measured the cytokines IL-2, IL-1ß, TNFa, IFN-?, and IL-17a which are well-known to mediate many inflammatory and autoimmune-related diseases. Remarkably, our compounds inhibited IL-17a and IL-2, had a modest effect on TNFa and had no effect on IL-1 ß and IFN-? secretion. This gives us insight into the mechanism of action of these drugs and paves the way forward for optimizing these compounds."

"With this important series of experiments, we have significantly de-risked the agonist program," says David Koos, Ph.D., Chairman & CEO Regen BioPharma Inc. "What this really means is the Company has identified a number of compounds that modulate checkpoint NR2F6. Recent developments show 3 compound groups that appear to be turbo-charged in the way they modulate NR2F6. The Company believes that these recent 3 compound groups just need some fine-tuning to be the basis for our autoimmune therapies. Additionally, using this information, we are now able to ramp up our inhibitor program which focuses on anti-cancer drugs."

About Regen BioPharma Inc.:

Regen BioPharma Inc. is a publicly traded biotechnology company (OTCQB: RGBP) and (OTCQB: RGBPP). The Company is focused on the immunology and immunotherapy space. The Company is focused on rapidly advancing novel technologies through pre-clinical and Phase I/II clinical trials. Currently, the Company is focused on small molecule therapies for treating cancer and autoimmune disorders.

Additional information on Regen BioPharma is available at http://www.regenbiopharmainc.com.

Disclaimer: This news announcement may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.

Contact Information:
Regen BioPharma Inc.
David R. Koos, Ph.D.
Chairman & Chief Executive Officer
Phone: [phone]
Fax: [phone]
[e-mail]
http://www.regenbiopharma.com
SOURCE Regen BioPharma, Inc.